Current Pharmacological Concepts in the Treatment of the Retinitis Pigmentosa.
Adv Exp Med Biol
; 1074: 439-445, 2018.
Article
em En
| MEDLINE
| ID: mdl-29721974
ABSTRACT
Retinitis pigmentosa (RP) encompasses a heterogeneous group of inherited retinal disorders characterized by progressive photoreceptor and/or retinal pigment epithelial (RPE) degenerations with a prevalence approximately 1 in 4000 in the general population. Over 70 causative genes have been defined in RP families, and a number of animal models have been identified so far. However there have been no widely recognized treatments able to recover or reverse the degenerating retina, to prevent the disease deterioration, ultimately to restore the remaining vision. Therapeutics advancements have been achieved including gene therapy, pharmacotherapy, cell replacement, neurotrophic factors, and retinal prosthesis. In this review, we focus on the pharmaceutical drugs for RP with emphases on the context of drug discovery, development, and clinical translation.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Retinose Pigmentar
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Adv Exp Med Biol
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
China